Loading…

Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis

•Using meta-analysis to study the efficacy of CBD in patients with anxiety disorders.•CBD-assisted therapy improved anxiety symptoms in patients with the disorder to varying degrees.•8 articles involving 245 patients with TRD were included in the meta-analysis.•More high-quality research-based trial...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 2024-09, Vol.339, p.116049, Article 116049
Main Authors: Han, Kevin, Wang, Jia-Yu, Wang, Peng-Yun, Peng, Yue-Chu-Han
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c293t-1b91ba21665b54874c75dee4eb993e0b8fe363915811f7ba2d1f3c5d713ec103
container_end_page
container_issue
container_start_page 116049
container_title Psychiatry research
container_volume 339
creator Han, Kevin
Wang, Jia-Yu
Wang, Peng-Yun
Peng, Yue-Chu-Han
description •Using meta-analysis to study the efficacy of CBD in patients with anxiety disorders.•CBD-assisted therapy improved anxiety symptoms in patients with the disorder to varying degrees.•8 articles involving 245 patients with TRD were included in the meta-analysis.•More high-quality research-based trials are needed to implement CBD-related treatments in future treatment guidelines for anxiety disorders. Cannabidiol (CBD), as one of the phytocannabinoids, has a wide range of therapeutic properties for various neuropsychiatric disorders due to central nervous system effects. These therapeutic properties demonstrated by preclinical and clinical studies encompass more than just anticonvulsant, anti-arthritic, analgesic, anti-inflammatory, antioxidant, antitumor, antiemetic, antipsychotic and neuroprotective effects. It has been hypothesized that CBD holds potential in the treatment of various neuropsychiatric and anxiety disorders. Thus, PRISMA was used as a guide for our systematic review. Eight of the 1550 articles screened in June 2023 were eligible for meta-analysis. Based on the 316 participants included in these eight articles, this meta-analysis revealed a substantial significant impact of CBD on anxiety with a considerable effect size (Hedges' g = -0.92, 95% CI -1.80 to -0.04). In addition, this meta-analysis focuses on the efficacy of CBD in treating anxiety disorders such as generalized anxiety disorder (GAD), social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD). However, caution should be exercised in interpreting our findings due to the limited size of the clinical sample, and additional trials ought to be carried out if deemed necessary.
doi_str_mv 10.1016/j.psychres.2024.116049
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3072800009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165178124003342</els_id><sourcerecordid>3072800009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c293t-1b91ba21665b54874c75dee4eb993e0b8fe363915811f7ba2d1f3c5d713ec103</originalsourceid><addsrcrecordid>eNqFkMtOHDEQRa0oKEyAX0BewqIHl90Pm1XIJAEkJDazt9x2tfCoX9ieJP338WiAbVa1Ofde1SHkEtgaGNQ3u_UcF_sSMK454-UaoGal-kRWIBteNMDFZ7LKYFVAI-GUfI1xxxjjoNQXciqk4qVUckW67QsGM-M-eUvnKeGYvOnp1FFrxtG03vmpp1eb7z-uqR-pGf96TAt1Pk7BYYi39I7GJSYczKEh4G-PfzLm6IDJFGY0_RJ9PCcnnekjXrzdM7L99XO7eSienu8fN3dPheVKpAJaBa3hUNdVW5WyKW1TOcQSW6UEslZ2KGqhoJIAXZNJB52wlWtAoAUmzsjVsXYO0-seY9KDjxb73ow47aMWrOEya2Aqo_URtWGKMWCn5-AHExYNTB8U651-V6wPivVRcQ5evm3s2wHdR-zdaQa-HQHMj2YdQUfrcbTofECbtJv8_zb-ARXWkTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3072800009</pqid></control><display><type>article</type><title>Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis</title><source>ScienceDirect Freedom Collection</source><creator>Han, Kevin ; Wang, Jia-Yu ; Wang, Peng-Yun ; Peng, Yue-Chu-Han</creator><creatorcontrib>Han, Kevin ; Wang, Jia-Yu ; Wang, Peng-Yun ; Peng, Yue-Chu-Han</creatorcontrib><description>•Using meta-analysis to study the efficacy of CBD in patients with anxiety disorders.•CBD-assisted therapy improved anxiety symptoms in patients with the disorder to varying degrees.•8 articles involving 245 patients with TRD were included in the meta-analysis.•More high-quality research-based trials are needed to implement CBD-related treatments in future treatment guidelines for anxiety disorders. Cannabidiol (CBD), as one of the phytocannabinoids, has a wide range of therapeutic properties for various neuropsychiatric disorders due to central nervous system effects. These therapeutic properties demonstrated by preclinical and clinical studies encompass more than just anticonvulsant, anti-arthritic, analgesic, anti-inflammatory, antioxidant, antitumor, antiemetic, antipsychotic and neuroprotective effects. It has been hypothesized that CBD holds potential in the treatment of various neuropsychiatric and anxiety disorders. Thus, PRISMA was used as a guide for our systematic review. Eight of the 1550 articles screened in June 2023 were eligible for meta-analysis. Based on the 316 participants included in these eight articles, this meta-analysis revealed a substantial significant impact of CBD on anxiety with a considerable effect size (Hedges' g = -0.92, 95% CI -1.80 to -0.04). In addition, this meta-analysis focuses on the efficacy of CBD in treating anxiety disorders such as generalized anxiety disorder (GAD), social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD). However, caution should be exercised in interpreting our findings due to the limited size of the clinical sample, and additional trials ought to be carried out if deemed necessary.</description><identifier>ISSN: 0165-1781</identifier><identifier>ISSN: 1872-7123</identifier><identifier>EISSN: 1872-7123</identifier><identifier>DOI: 10.1016/j.psychres.2024.116049</identifier><identifier>PMID: 38924898</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Anxiety ; Cannabidiol ; Meta-analysis ; Review ; SAD</subject><ispartof>Psychiatry research, 2024-09, Vol.339, p.116049, Article 116049</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c293t-1b91ba21665b54874c75dee4eb993e0b8fe363915811f7ba2d1f3c5d713ec103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38924898$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Han, Kevin</creatorcontrib><creatorcontrib>Wang, Jia-Yu</creatorcontrib><creatorcontrib>Wang, Peng-Yun</creatorcontrib><creatorcontrib>Peng, Yue-Chu-Han</creatorcontrib><title>Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis</title><title>Psychiatry research</title><addtitle>Psychiatry Res</addtitle><description>•Using meta-analysis to study the efficacy of CBD in patients with anxiety disorders.•CBD-assisted therapy improved anxiety symptoms in patients with the disorder to varying degrees.•8 articles involving 245 patients with TRD were included in the meta-analysis.•More high-quality research-based trials are needed to implement CBD-related treatments in future treatment guidelines for anxiety disorders. Cannabidiol (CBD), as one of the phytocannabinoids, has a wide range of therapeutic properties for various neuropsychiatric disorders due to central nervous system effects. These therapeutic properties demonstrated by preclinical and clinical studies encompass more than just anticonvulsant, anti-arthritic, analgesic, anti-inflammatory, antioxidant, antitumor, antiemetic, antipsychotic and neuroprotective effects. It has been hypothesized that CBD holds potential in the treatment of various neuropsychiatric and anxiety disorders. Thus, PRISMA was used as a guide for our systematic review. Eight of the 1550 articles screened in June 2023 were eligible for meta-analysis. Based on the 316 participants included in these eight articles, this meta-analysis revealed a substantial significant impact of CBD on anxiety with a considerable effect size (Hedges' g = -0.92, 95% CI -1.80 to -0.04). In addition, this meta-analysis focuses on the efficacy of CBD in treating anxiety disorders such as generalized anxiety disorder (GAD), social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD). However, caution should be exercised in interpreting our findings due to the limited size of the clinical sample, and additional trials ought to be carried out if deemed necessary.</description><subject>Anxiety</subject><subject>Cannabidiol</subject><subject>Meta-analysis</subject><subject>Review</subject><subject>SAD</subject><issn>0165-1781</issn><issn>1872-7123</issn><issn>1872-7123</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOHDEQRa0oKEyAX0BewqIHl90Pm1XIJAEkJDazt9x2tfCoX9ieJP338WiAbVa1Ofde1SHkEtgaGNQ3u_UcF_sSMK454-UaoGal-kRWIBteNMDFZ7LKYFVAI-GUfI1xxxjjoNQXciqk4qVUckW67QsGM-M-eUvnKeGYvOnp1FFrxtG03vmpp1eb7z-uqR-pGf96TAt1Pk7BYYi39I7GJSYczKEh4G-PfzLm6IDJFGY0_RJ9PCcnnekjXrzdM7L99XO7eSienu8fN3dPheVKpAJaBa3hUNdVW5WyKW1TOcQSW6UEslZ2KGqhoJIAXZNJB52wlWtAoAUmzsjVsXYO0-seY9KDjxb73ow47aMWrOEya2Aqo_URtWGKMWCn5-AHExYNTB8U651-V6wPivVRcQ5evm3s2wHdR-zdaQa-HQHMj2YdQUfrcbTofECbtJv8_zb-ARXWkTA</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Han, Kevin</creator><creator>Wang, Jia-Yu</creator><creator>Wang, Peng-Yun</creator><creator>Peng, Yue-Chu-Han</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240901</creationdate><title>Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis</title><author>Han, Kevin ; Wang, Jia-Yu ; Wang, Peng-Yun ; Peng, Yue-Chu-Han</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c293t-1b91ba21665b54874c75dee4eb993e0b8fe363915811f7ba2d1f3c5d713ec103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anxiety</topic><topic>Cannabidiol</topic><topic>Meta-analysis</topic><topic>Review</topic><topic>SAD</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, Kevin</creatorcontrib><creatorcontrib>Wang, Jia-Yu</creatorcontrib><creatorcontrib>Wang, Peng-Yun</creatorcontrib><creatorcontrib>Peng, Yue-Chu-Han</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, Kevin</au><au>Wang, Jia-Yu</au><au>Wang, Peng-Yun</au><au>Peng, Yue-Chu-Han</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis</atitle><jtitle>Psychiatry research</jtitle><addtitle>Psychiatry Res</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>339</volume><spage>116049</spage><pages>116049-</pages><artnum>116049</artnum><issn>0165-1781</issn><issn>1872-7123</issn><eissn>1872-7123</eissn><abstract>•Using meta-analysis to study the efficacy of CBD in patients with anxiety disorders.•CBD-assisted therapy improved anxiety symptoms in patients with the disorder to varying degrees.•8 articles involving 245 patients with TRD were included in the meta-analysis.•More high-quality research-based trials are needed to implement CBD-related treatments in future treatment guidelines for anxiety disorders. Cannabidiol (CBD), as one of the phytocannabinoids, has a wide range of therapeutic properties for various neuropsychiatric disorders due to central nervous system effects. These therapeutic properties demonstrated by preclinical and clinical studies encompass more than just anticonvulsant, anti-arthritic, analgesic, anti-inflammatory, antioxidant, antitumor, antiemetic, antipsychotic and neuroprotective effects. It has been hypothesized that CBD holds potential in the treatment of various neuropsychiatric and anxiety disorders. Thus, PRISMA was used as a guide for our systematic review. Eight of the 1550 articles screened in June 2023 were eligible for meta-analysis. Based on the 316 participants included in these eight articles, this meta-analysis revealed a substantial significant impact of CBD on anxiety with a considerable effect size (Hedges' g = -0.92, 95% CI -1.80 to -0.04). In addition, this meta-analysis focuses on the efficacy of CBD in treating anxiety disorders such as generalized anxiety disorder (GAD), social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD). However, caution should be exercised in interpreting our findings due to the limited size of the clinical sample, and additional trials ought to be carried out if deemed necessary.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>38924898</pmid><doi>10.1016/j.psychres.2024.116049</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0165-1781
ispartof Psychiatry research, 2024-09, Vol.339, p.116049, Article 116049
issn 0165-1781
1872-7123
1872-7123
language eng
recordid cdi_proquest_miscellaneous_3072800009
source ScienceDirect Freedom Collection
subjects Anxiety
Cannabidiol
Meta-analysis
Review
SAD
title Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A28%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20potential%20of%20cannabidiol%20(CBD)%20in%20anxiety%20disorders:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Psychiatry%20research&rft.au=Han,%20Kevin&rft.date=2024-09-01&rft.volume=339&rft.spage=116049&rft.pages=116049-&rft.artnum=116049&rft.issn=0165-1781&rft.eissn=1872-7123&rft_id=info:doi/10.1016/j.psychres.2024.116049&rft_dat=%3Cproquest_cross%3E3072800009%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c293t-1b91ba21665b54874c75dee4eb993e0b8fe363915811f7ba2d1f3c5d713ec103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3072800009&rft_id=info:pmid/38924898&rfr_iscdi=true